- Home
- ABP vs NERV Comparison
ABP vs NERV Comparison
Compare ABP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABP
- NERV
- Stock Information
- Founded
- ABP 2004
- NERV 2007
- Country
- ABP United States
- NERV United States
- Employees
- ABP N/A
- NERV N/A
- Industry
- ABP Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- ABP Health Care
- NERV Health Care
- Exchange
- ABP Nasdaq
- NERV Nasdaq
- Market Cap
- ABP 15.5M
- NERV 12.6M
- IPO Year
- ABP N/A
- NERV 2014
- Fundamental
- Price
- ABP $0.21
- NERV $1.77
- Analyst Decision
- ABP Strong Buy
- NERV Hold
- Analyst Count
- ABP 1
- NERV 1
- Target Price
- ABP $4.00
- NERV $5.00
- AVG Volume (30 Days)
- ABP 5.6M
- NERV 12.2K
- Earning Date
- ABP 08-18-2025
- NERV 08-05-2025
- Dividend Yield
- ABP N/A
- NERV N/A
- EPS Growth
- ABP N/A
- NERV N/A
- EPS
- ABP N/A
- NERV 0.83
- Revenue
- ABP $183,000.00
- NERV N/A
- Revenue This Year
- ABP N/A
- NERV N/A
- Revenue Next Year
- ABP N/A
- NERV N/A
- P/E Ratio
- ABP N/A
- NERV $2.18
- Revenue Growth
- ABP 88.66
- NERV N/A
- 52 Week Low
- ABP $0.15
- NERV $1.15
- 52 Week High
- ABP $11.19
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- ABP N/A
- NERV 57.10
- Support Level
- ABP N/A
- NERV $1.62
- Resistance Level
- ABP N/A
- NERV $1.83
- Average True Range (ATR)
- ABP 0.00
- NERV 0.09
- MACD
- ABP 0.00
- NERV -0.00
- Stochastic Oscillator
- ABP 0.00
- NERV 64.29
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.